• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

MindMaze Acquires NMI

Share:

December 3, 2018

Braintech leader MindMaze has today announced an acquisition that aims to significantly advance recovery for patients suffering from neurological diseases and injuries. The acquisition of Neuro Motor Innovations Corporation, which combines neuroscience and a novel form of animation – “neuroanimation” – to stimulate vast improvement of cognitive and motor functions, complements MindMaze’s current approach to neuro-rehabilitation. MindMaze will further develop and commercialize NMI’s technology that targets treatment of a wide range of neurological diseases and injuries from the acute through chronic stages. Additionally, the immersive cognitive-motor experiences can be used for healthy aging and wellness, as it has become apparent that complex movements are essential for maintaining executive cognitive function.

NMI is co-founded by neuroscientist Dr. John Krakauer, computer scientist Dr. Omar Ahmad, and software architect Promit Roy at The Kata Design Studio at The Johns Hopkins University Department of Neurology, and CEO Hoyt David Morgan. MindMaze acquires a perpetual license to NMI’s technology, and the company will continue its close relationship with Johns Hopkins. Dr. Krakauer will continue as a Malone Professor at Hopkins’ School of Medicine and the Malone Center for Engineering in Healthcare and also serve as Chief Medical and Scientific Advisor to MindMaze.

“It has long been known in the scientific community that enrichment – stimulating the brain by enhancing the physical and social environment – is important for neurological recovery in animal models, but there is no such equivalent in clinical settings for humans,” said Dr. Krakauer. “Our vision is to design a new platform that creates an immersive and enriching environment that integrates with existing MindMaze technology to deliver effective movement and cognitive therapy for many neurological diseases and injuries. The goal is to build a universal platform that can accelerate brain repair.”

MindMaze has created the first version of a global clinic-to-patient platform for neurological therapy, which uses an intuitive mind/machine interface to instantly decode brain and muscle signals. Powered by neuroscience, mixed reality, and artificial intelligence, MindMaze’s platform is used and proven across multiple industries. The company started in the healthcare industry, its MindMotion™ PRO, being the first neuro-rehabilitation solution to be FDA-cleared for patients in the United States. NMI will now work to create the next version of this platform.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“This acquisition of the Neuro Motor Innovations technology and the team is a very significant deal for MindMaze and one that offers huge promise for patients with neurological diseases and injuries,” said Tej Tadi, Founder, and CEO of MindMaze. “The integration of NMI’s technology into our platform creates the first multi-stage platform for neurological therapy.”

Date: December 3, 2018

Source: Cision

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Gout Drugs Market 2021 | Swot Analysis and Key DevelopmentGout Drugs Market 2021 | Swot Analysis and Key Development
  • Fitbit Partners with BMS, Pfizer on Early Atrial Fibrillation Detection ProjectFitbit Partners with BMS, Pfizer on Early Atrial Fibrillation Detection Project
  • Brainlab Announces the Majority Acquisition of MedphotonBrainlab Announces the Majority Acquisition of Medphoton
  • Pfizer Nears Deal to Combine Off-Patent Drug Unit With MylanPfizer Nears Deal to Combine Off-Patent Drug Unit With Mylan
  • Global Nephrology Drugs Market Envisioned to Generate a Revenue of $21,454.5 Million, Rising at a CAGR of 6.0% Over the Estimated Period from 2021-2028 [170-Pages] | Research DiveGlobal Nephrology Drugs Market Envisioned to Generate a Revenue of $21,454.5 Million, Rising at a CAGR of 6.0% Over the Estimated Period from 2021-2028 [170-Pages] | Research Dive
  • This Smart Baby Camera Can See When an Infant Stops Breathing
  • Bellicum Completes Sale of Houston FacilityBellicum Completes Sale of Houston Facility
  • Erich Mauff Acquires Super Voting Shares of Jushi Holdings Inc.Erich Mauff Acquires Super Voting Shares of Jushi Holdings Inc.

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications